PCSK9抑制-话题@MedSci

#PCSK9抑制#

50篇内容 | 1579人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1786883, encodeId=a2881e868836d, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=AHA 2021丨MK-0616（一种口服PCSK9抑制剂）的临床安全性、药代动力学和降低低密度脂蛋白胆固醇的疗效, objectType=article, longId=220423, objectId=65e722042367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65e722042367, replyNumber=0, likeNumber=94, createdTime=2022-03-28, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65e722042367, moduleTitle=AHA 2021丨MK-0616（一种口服PCSK9抑制剂）的临床安全性、药代动力学和降低低密度脂蛋白胆固醇的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65e722042367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786884, encodeId=0e901e86884db, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=Front Pharmacol：不同PCSK9抑制剂，哪个降脂力量更强？, objectType=article, longId=726544, objectId=1e53e265444e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e53e265444e, replyNumber=0, likeNumber=87, createdTime=2023-02-23, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e53e265444e, moduleTitle=Front Pharmacol：不同PCSK9抑制剂，哪个降脂力量更强？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e53e265444e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786880, encodeId=f7b81e868804e, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=JAHA：动脉粥样硬化疾病患者PCSK9抑制剂使用情况, objectType=article, longId=210568, objectId=111721056885, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=111721056885, replyNumber=0, likeNumber=64, createdTime=2021-10-30, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=111721056885, moduleTitle=JAHA：动脉粥样硬化疾病患者PCSK9抑制剂使用情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=111721056885)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786882, encodeId=6eb11e86882cf, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=JACC：高脂血症患者的福音！这些人能从强大的新型降脂药PCSK9抑制剂中获益！ , objectType=article, longId=215102, objectId=32d5215102e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32d5215102e2, replyNumber=0, likeNumber=82, createdTime=2022-06-21, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32d5215102e2, moduleTitle=JACC：高脂血症患者的福音！这些人能从强大的新型降脂药PCSK9抑制剂中获益！ , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32d5215102e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786881, encodeId=1cd91e8688127, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=J Clin Med：一项初步研究：PCSK9抑制剂依洛尤单抗对心血管疾病高危患者醛固酮分泌的影响, objectType=article, longId=213902, objectId=47232139022c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47232139022c, replyNumber=0, likeNumber=82, createdTime=2021-10-02, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47232139022c, moduleTitle=J Clin Med：一项初步研究：PCSK9抑制剂依洛尤单抗对心血管疾病高危患者醛固酮分泌的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47232139022c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786879, encodeId=fa0a1e86879fe, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=JAMA Cardiology：与他汀类药物和依折麦布相比，PCSK9抑制剂降低LDL-C的效果更显著, objectType=article, longId=203418, objectId=ecf82034184f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecf82034184f, replyNumber=0, likeNumber=78, createdTime=2021-03-04, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecf82034184f, moduleTitle=JAMA Cardiology：与他汀类药物和依折麦布相比，PCSK9抑制剂降低LDL-C的效果更显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ecf82034184f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786878, encodeId=5d601e868787c, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=HFSA 2020：PCSK9抑制剂有效降低心脏移植后的胆固醇水平, objectType=article, longId=202055, objectId=95c92020558c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95c92020558c, replyNumber=0, likeNumber=69, createdTime=2021-06-21, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95c92020558c, moduleTitle=HFSA 2020：PCSK9抑制剂有效降低心脏移植后的胆固醇水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95c92020558c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786876, encodeId=10141e868762f, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=JAHA：PCSK9抑制剂可改善HIV携带者冠脉健康, objectType=article, longId=197806, objectId=93af19e80665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93af19e80665, replyNumber=0, likeNumber=93, createdTime=2020-08-09, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93af19e80665, moduleTitle=JAHA：PCSK9抑制剂可改善HIV携带者冠脉健康, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93af19e80665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786877, encodeId=92941e86877eb, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=专家访谈:生命至上——PCSK9抑制剂值得被更多ACS患者使用, objectType=article, longId=201145, objectId=331b20114592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=331b20114592, replyNumber=0, likeNumber=79, createdTime=2021-05-26, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=331b20114592, moduleTitle=专家访谈:生命至上——PCSK9抑制剂值得被更多ACS患者使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=331b20114592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786873, encodeId=eab11e8687362, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=Circulation: PCSK9抑制剂还能抗栓！, objectType=article, longId=191429, objectId=921319142976, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=921319142976, replyNumber=0, likeNumber=92, createdTime=2021-03-19, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=921319142976, moduleTitle=Circulation: PCSK9抑制剂还能抗栓！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=921319142976)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786872, encodeId=95af1e868729a, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著, objectType=article, longId=190422, objectId=cfc8190422fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfc8190422fa, replyNumber=0, likeNumber=77, createdTime=2020-10-08, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfc8190422fa, moduleTitle=NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfc8190422fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786875, encodeId=ab6e1e8687563, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=Circulation：PCSK9抑制对静脉血栓栓塞（VTE）风险的影响, objectType=article, longId=195335, objectId=8002195335e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8002195335e0, replyNumber=0, likeNumber=95, createdTime=2021-02-09, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8002195335e0, moduleTitle=Circulation：PCSK9抑制对静脉血栓栓塞（VTE）风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8002195335e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786874, encodeId=c8301e8687409, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=JAHA：PCSK9抑制剂对其他降脂药物的使用情况的影响, objectType=article, longId=192961, objectId=37e419296119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37e419296119, replyNumber=0, likeNumber=75, createdTime=2021-01-02, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37e419296119, moduleTitle=JAHA：PCSK9抑制剂对其他降脂药物的使用情况的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37e419296119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786870, encodeId=08d21e86870c6, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=Curr Atheroscle Rep：从机制到实践，PCSK9抑制剂成为降脂治疗新选择, objectType=article, longId=180194, objectId=6961180194ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6961180194ec, replyNumber=0, likeNumber=81, createdTime=2020-03-09, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6961180194ec, moduleTitle=Curr Atheroscle Rep：从机制到实践，PCSK9抑制剂成为降脂治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6961180194ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786869, encodeId=59821e86869f9, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=Medicines公司的一年两次PCSK9抑制剂抗动脉粥样硬化达到III期研究的主要目标, objectType=article, longId=178240, objectId=d4021e824003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4021e824003, replyNumber=0, likeNumber=70, createdTime=2019-11-15, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4021e824003, moduleTitle=Medicines公司的一年两次PCSK9抑制剂抗动脉粥样硬化达到III期研究的主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4021e824003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786871, encodeId=3cc21e86871a3, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=Circulation：PCSK9抑制剂阿利库单抗对急性冠脉综合征患者卒中风险的影响, objectType=article, longId=185077, objectId=c42a1850e7c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c42a1850e7c0, replyNumber=0, likeNumber=87, createdTime=2020-09-20, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c42a1850e7c0, moduleTitle=Circulation：PCSK9抑制剂阿利库单抗对急性冠脉综合征患者卒中风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c42a1850e7c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786868, encodeId=60801e868681c, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=JACC：PCSK9抑制剂对慢性肾脏疾病的影响, objectType=article, longId=169024, objectId=3826169024c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3826169024c3, replyNumber=0, likeNumber=68, createdTime=2019-12-30, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3826169024c3, moduleTitle=JACC：PCSK9抑制剂对慢性肾脏疾病的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3826169024c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786865, encodeId=572c1e8686551, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=临床和经济评论研究所（ICER）：PCSK9抑制剂Alirocumab治疗高胆固醇症的证据更新, objectType=article, longId=160533, objectId=43881605336e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43881605336e, replyNumber=0, likeNumber=79, createdTime=2019-04-13, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43881605336e, moduleTitle=临床和经济评论研究所（ICER）：PCSK9抑制剂Alirocumab治疗高胆固醇症的证据更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43881605336e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786864, encodeId=90841e8686413, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=Circulation：脂蛋白（a）、PCSK9抑制和心血管风险, objectType=article, longId=154973, objectId=eda61549e317, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eda61549e317, replyNumber=0, likeNumber=67, createdTime=2019-06-30, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eda61549e317, moduleTitle=Circulation：脂蛋白（a）、PCSK9抑制和心血管风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eda61549e317)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786858, encodeId=0ee61e8685874, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, objectTitle=李建军：药物机制是PCSK9抑制剂临床获益的有力保证, objectType=article, longId=148232, objectId=5995148232b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5995148232b3, replyNumber=0, likeNumber=75, createdTime=2018-09-15, rootId=0, userName=wjywjy, userId=1072181, projectId=1, avatar=/img/user_icon.png, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5995148232b3, moduleTitle=李建军：药物机制是PCSK9抑制剂临床获益的有力保证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5995148232b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PCSK9抑制

2020-05-29

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

AHA 2021丨MK-0616（一种口服PCSK9抑制剂）的临床安全性、药代动力学和降低低密度脂蛋白胆固醇的疗效

2022-03-28

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

Front Pharmacol：不同PCSK9抑制剂，哪个降脂力量更强？

2023-02-23

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

JAHA：动脉粥样硬化疾病患者PCSK9抑制剂使用情况

2021-10-30

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

JACC：高脂血症患者的福音！这些人能从强大的新型降脂药PCSK9抑制剂中获益！

2022-06-21

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

J Clin Med：一项初步研究：PCSK9抑制剂依洛尤单抗对心血管疾病高危患者醛固酮分泌的影响

2021-10-02

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

JAMA Cardiology：与他汀类药物和依折麦布相比，PCSK9抑制剂降低LDL-C的效果更显著

2021-03-04

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

HFSA 2020：PCSK9抑制剂有效降低心脏移植后的胆固醇水平

2021-06-21

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

JAHA：PCSK9抑制剂可改善HIV携带者冠脉健康

2020-08-09

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

专家访谈:生命至上——PCSK9抑制剂值得被更多ACS患者使用

2021-05-26

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

Circulation: PCSK9抑制剂还能抗栓！

2021-03-19

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著

2020-10-08

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

Circulation：PCSK9抑制对静脉血栓栓塞（VTE）风险的影响

2021-02-09

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

JAHA：PCSK9抑制剂对其他降脂药物的使用情况的影响

2021-01-02

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

Curr Atheroscle Rep：从机制到实践，PCSK9抑制剂成为降脂治疗新选择

2020-03-09

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

Medicines公司的一年两次PCSK9抑制剂抗动脉粥样硬化达到III期研究的主要目标

2019-11-15

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

Circulation：PCSK9抑制剂阿利库单抗对急性冠脉综合征患者卒中风险的影响

2020-09-20

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

JACC：PCSK9抑制剂对慢性肾脏疾病的影响

2019-12-30

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

临床和经济评论研究所（ICER）：PCSK9抑制剂Alirocumab治疗高胆固醇症的证据更新

2019-04-13

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

Circulation：脂蛋白（a）、PCSK9抑制和心血管风险

2019-06-30

wjywjy (审核中...)

前往app查看评论内容

#PCSK9抑制#

李建军：药物机制是PCSK9抑制剂临床获益的有力保证

2018-09-15

科室
- - 订阅+
  - 更多科室
工具
服务